• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mutations and thrombosis in essential thrombocythemia.

作者信息

Guglielmelli Paola, Gangat Naseema, Coltro Giacomo, Lasho Terra L, Loscocco Giuseppe Gaetano, Finke Christy M, Morsia Erika, Sordi Benedetta, Szuber Natasha, Hanson Curtis A, Pardanani Animesh, Vannucchi Alessandro M, Tefferi Ayalew

机构信息

Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

Divisions of Hematology, Mayo Clinic, Rochester, MN, USA.

出版信息

Blood Cancer J. 2021 Apr 27;11(4):77. doi: 10.1038/s41408-021-00470-y.

DOI:10.1038/s41408-021-00470-y
PMID:33907189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8079671/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae48/8079671/06cd227a8f71/41408_2021_470_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae48/8079671/06cd227a8f71/41408_2021_470_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae48/8079671/06cd227a8f71/41408_2021_470_Fig1_HTML.jpg

相似文献

1
Mutations and thrombosis in essential thrombocythemia.原发性血小板增多症中的突变与血栓形成
Blood Cancer J. 2021 Apr 27;11(4):77. doi: 10.1038/s41408-021-00470-y.
2
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.钙网蛋白突变不会改变1150例原发性血小板增多症患者中用于预测血栓形成风险的IPSET评分。
Blood. 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676.
3
Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia.儿童及青少年原发性血小板增多症不同的驱动基因突变谱
Pediatr Blood Cancer. 2015 Jan;62(1):175-6. doi: 10.1002/pbc.25190. Epub 2014 Aug 17.
4
JAK2, MPL, and CALR mutations in children with essential thrombocythemia.原发性血小板增多症患儿的JAK2、MPL和CALR基因突变
Int J Hematol. 2016 Aug;104(2):266-7. doi: 10.1007/s12185-016-2022-2. Epub 2016 May 21.
5
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.原发性血小板增多症中的突变与血栓形成：与年龄和血栓形成史的预后相互作用。
Eur J Haematol. 2015 Jan;94(1):31-6. doi: 10.1111/ejh.12389. Epub 2014 Dec 4.
6
JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.真性红细胞增多症和主要血栓并发症中的JAK2 V617F、MPL及CALR突变：一项单机构回顾性分析
Pathol Oncol Res. 2015 Jul;21(3):751-8. doi: 10.1007/s12253-014-9885-4. Epub 2015 Jan 10.
7
CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia.190例原发性血小板增多症患者的CALR和ASXL1基因突变分析。
Leuk Lymphoma. 2015 Mar;56(3):820-2. doi: 10.3109/10428194.2014.939963. Epub 2014 Aug 13.
8
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.CALR 突变、MPL 突变和三阴性可识别原发性骨髓纤维化中血管风险最低的患者。
Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8.
9
Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
10
Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis.原发性血小板增多症和骨髓纤维化中突变状态与形态学改变的相关性
Pathology. 2018 Oct;50(6):671-674. doi: 10.1016/j.pathol.2018.02.005. Epub 2018 Aug 7.

引用本文的文献

1
Warm Autoimmune Hemolytic Anemia as a Rare Presentation of Pre-fibrotic Primary Myelofibrosis.温抗体型自身免疫性溶血性贫血作为纤维化前期原发性骨髓纤维化的罕见表现。
Cureus. 2024 Dec 5;16(12):e75155. doi: 10.7759/cureus.75155. eCollection 2024 Dec.
2
Molecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasm in a Moroccan Population.摩洛哥人群中 BCR-ABL1 阴性骨髓增殖性肿瘤的分子特征。
Asian Pac J Cancer Prev. 2024 Nov 1;25(11):4013-4025. doi: 10.31557/APJCP.2024.25.11.4013.
3
Long-term risks of cardiovascular-specific mortality among myeloproliferative neoplasms patients.

本文引用的文献

1
Young platelet millionaires with essential thrombocythemia.患有原发性血小板增多症的年轻血小板“富翁”。
Am J Hematol. 2021 Apr 1;96(4):E93-E95. doi: 10.1002/ajh.26114. Epub 2021 Feb 18.
2
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.真性红细胞增多症和原发性血小板增多症：2021 年诊断、风险分层和治疗更新。
Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23.
3
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.
骨髓增殖性肿瘤患者心血管特异性死亡的长期风险。
Ther Adv Hematol. 2024 Oct 28;15:20406207241290886. doi: 10.1177/20406207241290886. eCollection 2024.
4
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.体细胞基因突变对骨髓纤维化患者血栓形成风险的影响。
Leukemia. 2024 Nov;38(11):2483-2486. doi: 10.1038/s41375-024-02389-2. Epub 2024 Aug 30.
5
Thrombotic Prediction Model Based on Epigenetic Regulator Mutations in Essential Thrombocythemia Patients Using Survival Analysis in Recurrent Events.基于生存分析中复发性事件的表观遗传调控因子突变的原发性血小板增多症患者血栓预测模型。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241263099. doi: 10.1177/10760296241263099.
6
Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis.评估绝对中性粒细胞、淋巴细胞和血小板计数及其比值作为纤维化前期和明显骨髓纤维化患者血栓形成风险预测指标的价值。
Life (Basel). 2024 Apr 17;14(4):523. doi: 10.3390/life14040523.
7
Impact of and V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.JAK2 V617F突变对原发性血小板增多症临床病程及疾病转归的影响：一项针对土耳其患者的多中心回顾性研究
Turk J Haematol. 2024 Mar 1;41(1):26-36. doi: 10.4274/tjh.galenos.2024.2023.0430.
8
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.探讨与异常部位静脉血栓形成相关的骨髓增殖性肿瘤的分子方面：文献回顾与最新见解。
Int J Mol Sci. 2024 Jan 26;25(3):1524. doi: 10.3390/ijms25031524.
9
One thousand patients with essential thrombocythemia: the Mayo Clinic experience.一千例原发性血小板增多症患者：梅奥诊所的经验。
Blood Cancer J. 2024 Jan 18;14(1):11. doi: 10.1038/s41408-023-00972-x.
10
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.一千例原发性血小板增多症患者：佛罗伦萨-CRIMM 研究经验。
Blood Cancer J. 2024 Jan 18;14(1):10. doi: 10.1038/s41408-023-00968-7.
突变增强的原发性血小板增多症和真性红细胞增多症国际预后系统。
Br J Haematol. 2020 Apr;189(2):291-302. doi: 10.1111/bjh.16380. Epub 2020 Jan 16.
4
Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.年轻人中的骨髓增殖性肿瘤：梅奥诊所对 361 名年龄在 40 岁或以下的患者的经验。
Am J Hematol. 2018 Dec;93(12):1474-1484. doi: 10.1002/ajh.25270. Epub 2018 Sep 27.
5
Mayo CALR mutation type classification guide using alpha helix propensity.使用α螺旋倾向的梅奥CALR突变类型分类指南
Am J Hematol. 2018 May;93(5):E128-E129. doi: 10.1002/ajh.25065. Epub 2018 Feb 24.
6
Targeted deep sequencing in polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症中的靶向深度测序
Blood Adv. 2016 Nov 22;1(1):21-30. doi: 10.1182/bloodadvances.2016000216. eCollection 2016 Nov 29.
7
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
8
Refining prognostication of thrombosis in ET.改善原发性血小板增多症血栓形成的预后评估
Am J Hematol. 2016 Jun;91(4):361-3. doi: 10.1002/ajh.24320.
9
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.钙网蛋白突变不会改变1150例原发性血小板增多症患者中用于预测血栓形成风险的IPSET评分。
Blood. 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676.
10
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.原发性血小板增多症中的突变与血栓形成：与年龄和血栓形成史的预后相互作用。
Eur J Haematol. 2015 Jan;94(1):31-6. doi: 10.1111/ejh.12389. Epub 2014 Dec 4.